Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10878340 | 0.85 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4656897 | 0.84 | SLC6A4 (0.69) | SLC6A4SLC6A2OPRM1SLC6A3 | |
| SCHEMBL16565548 | 0.82 | P2RX7 (0.52) | SLC6A4SLC6A2OPRM1SLC6A3 | |
| SCHEMBL4656093 | 0.82 | SLC6A4 (0.73) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27997201 | 0.82 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL15862815 | 0.82 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14144428 | 0.80 | SLC6A4 (0.48) | SLC6A4SLC6A2OPRM1SLC6A3 | |
| SCHEMBL17888243 | 0.77 | OPRM1 (0.50) | OPRM1SLC6A3 | |
| SCHEMBL10266059 | 0.77 | OPRD1 (0.42) | SLC6A4OPRM1 | |
| SCHEMBL13400265 | 0.76 | CCR5 (0.53) | SLC6A4SLC6A2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245572-A1 | Naphthyl ether compounds and their use | OLINK AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1546101-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004022539-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245572-A1 | Naphthyl ether compounds and their use | NR4A1, NPM1, H1-4 | SLC6A4 3111/4885SLC6A2 2909/4885OPRM1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.